The Readout Loud
248: The next CRISPR fight, cheaper insulin, & an FDA shuffle
This episode isn’t summarized yet
Create a free account and summarize it. In a few minutes you’ll have the key takeaways and a section-by-section summary.
Show notes
Our colleague Allison DeAngelis joins us to explain how the latest CRISPR breakthrough is shaping up to be a free-for-all among a multitude of companies and labs, including some of the biggest names in biotech. We also discuss the latest news in the life sciences, including Eli Lilly slashing the cost of insulin, succession at the FDA, and how pandemic boom times have turned to bust.